Drug Search Results
More Filters [+]

Galicaftor

Alternative Names: galicaftor, glpg-2222, glpg2222, glpg 2222, abbv-2222, abbv 2222, abbv2222
Latest Update: 2024-07-16
Latest Update Note: News Article

Product Description

ABBV-2222 (formerly GLPG2222) is a type of CFTR modulator called a corrector. (Sourced from: )

Mechanisms of Action: CFTR Modulator

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Galapagos
Company Location: 2800 MECHELEN C9 00000
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Galicaftor

Countries in Clinic: United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 1: Cystic Fibrosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

M23-492 FE

P1

Completed

Cystic Fibrosis

2022-12-21

28%

M23-492 FE

P1

Completed

Cystic Fibrosis

2022-12-21

28%

ABBV-576 DDI

P1

Completed

Cystic Fibrosis

2022-11-29

21%

ABBV-576 DDI

P1

Completed

Cystic Fibrosis

2022-11-29

21%

Recent News Events